CAR T-cell therapy for recurrent brain tumors
Part of Cancer clinical trials.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a recurrent high-grade glioma (grade III or IV) or a lower-grade tumor that now looks high-grade on scans
- Your tumor is in one area (unifocal) in the top part of the brain, not in sensitive spots like the brainstem or motor cortex
- If you take steroids (like dexamethasone), your daily dose is 4 mg or less, and you have not increased it recently
- You have adequate kidney and liver function and good blood counts
- You are able to undergo surgery to remove most of the tumor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
Hear when a new Recurrent Malignant Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.